Cephalon, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1987, the company has achieved significant milestones, including its acquisition by Teva Pharmaceutical Industries in 2011, which bolstered its market presence. Specialising in innovative treatments for neurological disorders, pain management, and cancer, Cephalon is renowned for its unique product offerings, such as Provigil and Nuvigil, which address sleep disorders and enhance wakefulness. With a strong commitment to research and development, Cephalon has established itself as a leader in the pharmaceutical sector, consistently delivering high-quality solutions that improve patient outcomes. Its strategic focus on niche therapeutic areas has solidified its position in the competitive biopharmaceutical landscape.
We don't have data for Cephalon, Inc., but we can show you information about their parent organization instead.
View parent company